Human Genome Sciences Inc. of Rockville said yesterday that it has agreed to license the rights to sell future HGS products in Japan to Takeda Chemical Industries Ltd. in exchange for $5 million and a future royalty stream.
Human Genome spokeswoman Nancy Broadbent said the products involved have not begun clinical trials. That means they probably are years away from government marketing approval.
The deal also provides that Human Genome Sciences will obtain U.S. marketing rights to products that Takeda develops based on the Maryland company's gene sequencing research.
Takeda gained access to the database through a sublicensing agreement with SmithKline Beecham PLC, the British drug giant that has a license from HGS to market therapeutic vaccine and diagnostic products and services developed from gene data discovered by the SmithKline-Human Genome alliance.